Navigation Links
Defending against chemical acts of terrorism
Date:6/8/2012

ions into the gene encoding a target enzyme, in this case PON1. The mutated versions of the gene are then put back into bacteria, which produce the enzymes for testing. The goal was to end up with enzymes capable of detoxifying G-type nerve agents before those nerve agents could reach their target and cause harm. Those that passed the initial test went on to further rounds of evolution and testing.

After four rounds of evolution, the researchers obtained PON1 variants that worked up to 340 times better than those produced previously. Overall, the researches reported that the PON1 variants showed 40- to 3,400-fold higher efficiency than the normal enzyme in metabolizing the three most toxic G-type nerve agents.

These new and improved PON1 enzymes have become promising candidates for use as preventive and postexposure treatments in the event of a terrorist attack.

"We hope that our enzymes would be able to act together with currently available drugs to improve survival rates following intoxication," Goldsmith said. More broadly, the findings show the power of laboratory evolution to completely reshape existing enzymes for a variety of uses.


'/>"/>

Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Defending against chemical acts of terrorism
2. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
3. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
4. MU researchers identify key plant immune response in fight against bacteria
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Nanosurgery and the fight against cancer: Major breakthrough at Polytechnique Montral
7. 3M Withdraws Blackmail Claims Against Harvey Boulter From New York Court
8. X-BODY BioSciences to Present Novel Methods of Selecting for Antibodies Against Targets on Live Cells at CHIs Protein Engineering Summit
9. The Italian Institute of Prophylaxis against Animal Diseases (IZS) to test effectiveness of BeesFree Inc.s Technology in Combating Colony Collapse Disorder
10. Elsevier and Federation of Biochemical Societies Launch New Journal: FEBS Open Bio
11. Bio architecture lab technology converts seaweed to renewable fuels and chemicals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... King of Prussia, PA (PRWEB) May 21, 2015 ... that Julia O’Neill has joined the firm as senior ... more than 30 years of experience in the management ... the vaccines, biologics, pharmaceutical and chemical industries. , “We’re ... enhance our longstanding capabilities in data analytics,” said Dr. ...
(Date:5/20/2015)... , May 20, 2015  Select Medical ... the Federal Trade Commission granted early termination of ... Improvements Act of 1976, as amended, applicable to ... Acquisition Corporation, a joint venture that Select has ... As previously announced, MJ Acquisition Corporation ...
(Date:5/20/2015)... , May 20, 2015  Haemonetics Corporation (NYSE: ... President & CEO, will present at The Jefferies 2015 ... on June 1 st , 2015 at 8:30am ... Mr. Concannon,s presentation live via webcast at: ... (NYSE: HAE ) is a global healthcare company ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... is making,progress in the development of sustainable biofuels. The recent first crop of,genetically modified poplars of the Flemish Institute for Biotechnology (VIB),will be modified into bioethanol in a Flemish-Dutch pilot ... , ... ... ...
... He is joined by scientists scattered from Ann Arbor to Osaka on the annual Thomson Reuters list of the world,s 12 hottest researchers. , ... , ... ... ...
... ... Kimberly Thompson wins $5,000 in CUNY Nobel Science Challenge. , ... New York, NY (Vocus) March 12, 2010 -- Borough ... the economics category of the 2009 CUNY Nobel Science Challenge—as well as $5,000 as an ...
Cached Biology Technology:Bio Base Europe: Flanders and the Netherlands Cooperate on Biofuels From Genetically Modified Poplars 2Bio Base Europe: Flanders and the Netherlands Cooperate on Biofuels From Genetically Modified Poplars 3Thomson Reuters Names the World's 'Hottest' Researchers 2Thomson Reuters Names the World's 'Hottest' Researchers 3Thomson Reuters Names the World's 'Hottest' Researchers 4Thomson Reuters Names the World's 'Hottest' Researchers 5BMCC Student—the Only Community College Winner—Lands Grand Prize in Nobel Science Challenge 2
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... German . The Deutsche Forschungsgemeinschaft (DFG, German Research ... was taken by the DFG,s Senate at its February session ... with the opportunity to address current and urgent issues in ... Like all DFG Research Units, the new facilities will take ...
... well-known limestone cave in East Timor have been discovered by a ... archaeologists and palaeontologists were working in Lene Hara Cave on the ... floor at a colleague sitting on a ledge, my head torch ... Ken Aplin said. "I shone the torch around and saw ...
... The daughters of rats who took folic acid supplements before ... twice as high as other rats, according to a new ... a faster rate, according to the study led by Dr. ... Kim stressed more research needs to be done to determine ...
Cached Biology News:DFG establishes 9 new research units 2DFG establishes 9 new research units 3DFG establishes 9 new research units 4DFG establishes 9 new research units 5DFG establishes 9 new research units 6DFG establishes 9 new research units 7Giant rats lead scientists to ancient face carvings 2Offspring of female rats given folic acid supplements develop more breast cancer 2
Request Info...
... Kit Components , 25 g Blocking Reagent , ... 10 ml T7 Elution Buffer , 0.2 ml ... , 0.2 ml BLT5615 glycerol stock , 1010 ... Negative Control Lysate , 50 l S-protein HRP Conjugate ...
Attoglow Western Blot Enhancing Kit contains Millennium Enhancer which can significantly boost Western blot signals, and is compatible with other enhancing mechanisms to achieve multiplied enhancing ...
...
Biology Products: